Relationship of type 2 diabetes mellitus and cardiovascular pathology: significance of glycemic control on the way to solving the problem

Cardiovascular diseases (CVD) is the most frequent cause of death in diabetes mellitus (DM) patients, and diabetes, in turn, significantly increases the risk of cardiovascular pathology, and therefore the implementation of measures for primary and secondary prevention of complications in patients with DM and CVD is a topical direction of modern medicine. In case of diabetes, CVDs occur 2-5 times more frequently than in persons without this pathology. There is also a high risk of developing conditions such as coronary heart disease (CHD), myocardial infarction (MI), arterial hypertension (AH), acute cerebrovascular disease (ACVD). Thus, 69% of patients with DM have dyslipidemia, 80% - AH, 50-75% - diastolic dysfunction, 12-22% - chronic heart failure (CHF). Mortality from MI among patients with DM is 1.5-2 times higher than among people who do not suffer from this disease, both in the acute stage of MI, and in prolonged observation. Therefore, it is necessary to work out a common approach to this problem on behalf of both cardiologists and endocrinologists, and patients, which will improve the quality of treatment and prevent the development of DM complications.

Intensive control of glycemia in patients is essential to prevent the development and progression of DM complications, which is proved by a number of fundamental studies presented in this article. Regular and competent self-control by patients allows maintaining normal or close to normal blood glucose levels. It is a reliable, convenient and patient-friendly way to prevent the development of diabetic complications.

1. Williams R. (ed.) IDF Diabetes Atlas Committee. 9th ed. 2019. Available at: https://www.diabetesatlas.org/en/sections/demographic-and-geographic-outline.html.

2. Neaton J.D., Wentworth D.N., Cutler J. et al. Multiple Risk Factor Intervention trial Research Group. Annals of Epidemiology. 1993;3(5):493-499. doi: 10.1016/1047-2797(93)90103-b.

3. Ametov A.S., Kochergin I.I. The Role and place of domestic products Gliformin and Glidecam in the treatment of diabetes 2 type. RMZH. Ehndokrinologiya = RMJ. Endocrinology. 2011;(27):1678. (In Russ.) Available at: https://www.rmj.ru/articles/endokrinologiya/Roly_i_mesto_otechestvennyh_preparatov_Gliformin_i_Glimekomb_v_lechenii_saharnogo_diabeta_2_tipa/.

4. Betteridge D.J. Epidemiology of the Cardiac Complications of Type 2 Diabetes Mellitus. Medicographia. 2001;(23):95-99.

5. Balabolkin M.I., Klebanova E.M., Kreminskaya V.M. Treatment of diabetes and its complications. Physicians' Guide. Moscow: Medicine; 2005. 512 p. (In Russ.)

6. Tregubenko E.V., Klimkin A.S. Peculiarities of the Course of Coronary Heart Disease in Patients with Type 2 Diabetes Mellitus. Trudnyy patsient = Difficult patient. 2015;13(7):26-29. (In Russ.) Available at: http://t-pacient.ru/articles/9040/.

7. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease: the Frammingam study. JAMA. 1979;241(19):2035-2038. doi: 10.1001/jama.241.19.2035.

8. Morozova T.E., Andrushchishina T.B. Arterial hypertension in patients with diabetes mellitus: an individualized choice of antihypertensive medications. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2011;(2):72-77. (In Russ.) Available at: https://russjcardiol.elpub.ru/jour/article/viewFile/1152/880.

9. Runihin A.U., Demidova I.U. Arterial hypertension in type 2 diabetes melli-tus patients: features of pathogenesis and treatment tactics. Farmateka = Pharmateca. 2002;(5):9-13. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/5755.

10. Oschepkova E.V. Mortality from cardiovascular diseases in the Russian Federation and ways to reduce it. Kardiologiya = Cardiology. 2009;(2):267-272. Available at: https://lib.medvestnik.ru/articles/Smertnost-naseleniya-ot-serdechno-sosudistyh-zabolevanii-v-Rossiiskoi-Federacii-v-2001-2006-gg-i-puti-po-ee-snijeniu.html.

11. Betuganova L.V., Elgarov A.A., Baysultanova M.G., Elgarov M.A., Kalmykova M.A. Myocardial infarction - frequency, professional, clinical and sex-related peculiarities, medical rehabilitation. Kardiosomatika = Cardiosomatics. 2014;5(2):10-14. (In Russ.) Available at: https://elibrary.ru/item.asp?id=22441917.

12. Van Heerebeek L., Hamdani N., Handoko M.L. et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117(1):43-51. doi: 10.1161/CIRCULATIONAHA.107.728550.

13. Hartog J.W., Voors A.A., Bakker S.J. et al. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. European Journal Heart Failure. 2007;9(12):1146-1155. doi: 10.1016/j.ejheart.2007.09.009.

14. Raposeiras-Roubin S., Rodino-Janeiro B.K., Grigorian-Shamagian L., Moure-Gonzalez M. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. European Journal Heart Failure. 2010;12(10):1092-1100. doi: 10.1093/eurjhf/hfq117.

15. Markus M.R., Stritzke J., Wellmann J., Duderstadt S. et al. Implications of prevalent and incident diabetes mellitus on left ventricular geometry and function in the ageing heart: the MONICA/KORA Augsburg cohort study. Nutrition, Metabolism Cardiovascular Diseases. 2011;21(3):189-196. doi: 10.1016/j.numecd.2009.09.005.

16. From A.M., Scott C.G., Chen H.H. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. Journal of the American College Cardiology. 2010;55(4):300-305. doi: 10.1016/j.jacc.2009.12.003.

17. Zaccardi F., Pitocco D., Ghirlanda G. Glycemic risk factors of vascular complications: the role of glycemic variability. Diabetes Metab Res Rev. 2009;25(3):199-207. doi: 10.1002/dmrr.938.

18. Kondratyeva L.V. Statins as a necessary component of 2nd type diabetes mellitus therapy. Lechashchiy vrach = Attending physician. 2013;(3):12-18. (In Russ.) Available at: https://www.lvrach.ru/2013/03/15435647/.

19. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study Group. Lancet. 1998;352(9131):854-865. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9742977/.

20. Gaede P., Pedersen O. Intensive integrated therapy of type 2 Diabetes. Implications for long-term prognosis. Diabetes. 2004;53(3):39-47. doi: 10.2337/diabetes.53.suppl_3.s39.

21. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 Diabetes. N Engl J Med. 2003;348(5):383-393. doi: 10.1056/NEJMoa021778.

22. Shichiri M., Kishikawa H., Ohkubo Y., Wake N. Long-term Results of Kumamoto Study on Optimal Diabetes Control in Type 2 Diabetes Patients. Diabetes Care. 2000;23(Suppl 2):21-29. Available at: https://www.ncbi.nlm.nih.gov/pubmed/10860187.

23. Wilkinson C.P., Ferris F.L., Klein R., Lee P.P., Agardh C.D. et al. Proposed international clinical diabetic Retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-1682. doi: 10.1016/S0161-6420(03)00475-5.

24. Kohnert K.D., Augstein P., Zander E. et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care. 2009;32(6):1058-1062. doi: 10.2337/dc08-1956.

25. Mayer-Davis E.J., Monaco J.H., Hoen H.M., Carmichael S., Vitolins M.Z., Rewers M.J. et al. Dietary fat and insulin sensitivity in a triethnic population: the role of obesity. The Insulin Resistance Atherosclerosis Study (IRAS). American Journal Clinical Nutrition. 1997;65(1):79-87. doi: 10.1093/ajcn/65.1.79.

26. Demidova T.Yu. Etiopathogenetic role of insulin resistance in the development of metabolic and vascular disorders in type 2 diabetes mellitus. Farmateka = Pharmateca. 2010;(16):18-24. (In Russ.) Available at: https://lib.medvestnik.ru/articles/Etiopatogeneticheskaya-rol-insulinorezistentnosti-v-razvitii-metabolicheskih-i-sosudistyh-narushenii-pri-saharnom-diabete-tipa-2.html.

27. Ametov A.S., Sokareva E.V. Violation of lipid metabolism in type 2 diabetes and their correction. RMZH = RMJ. 2009;(24):1586-1590. (In Russ.) Available at: https://www.rmj.ru/articles/endokrinologiya/Narusheniya_lipidnogo_obmena__pri_saharnom_diabete_2go_tipa_i_ih_korrekciya/.

28. Ametov A.S., Dedov I.I. Endocrinology-yesterday, today, tomorrow. RMZH = RMJ. 2005;(6):288–294. (In Russ.) Available at: https://www.rmj.ru/articles/endokrinologiya/Endokrinologiya__vchera_segodnya_zavtra/.

29. Dedov I.I., Shestakova M.V. Diabetes mellitus: physician’s guide. Moscow: Universum publishing; 2003. 455 p. (In Russ.) Available at: https://search.rsl.ru/ru/record/01002439959.

30. Manukhina E.B., Smirin B.V., Malyshev I.Yu. et al. The Deposit of nitric oxide in the cardiovascular system. Izvestiya RAN. Seriya biologicheskaya = Biology Bulletin. 2002;(3):46–52. (In Russ.)

31. Belovol A.N., Knyazkova I.I. Cardiovascular disease and diabetes. Health protection of Ukraine. 2014;(3):28–29. (In Russ.) Available at: http://repo.knmu.edu.ua/handle/123456789/8535.

32. Kononenko I.V., Smirnova O.M. The importance of combined glycemic control in patients with type 2 diabetes mellitus. Problemy ehndokrinologii = Problems of endocrinology. 2010;5:43–51. (In Russ.) Available at: https://www.mediasphera.ru/issues/problemy-endokrinologii/2010/5/030375-9660201057.

33. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine. 1993;329(14):977–986. Available at: https://www.nejm.org/doi/pdf/10.1056/NEJM199309303291401.

34. Stettler C., Allemann S., Jüni P. et al. Glycemic control and macrovascular disease in type 1 and 2 diabetes mellitus. Meta-analysis of randomized trials. American Heart Journal. 2006;152(1):27–38. doi: 10.1016/j.ahj.2005.09.015.

35. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: eff ects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140–1147. doi: 10.1007/s00125-007-0599-y.

36. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., Miller M.E., Byington R.P. et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743.

37. ADVANCE Collaborative Group, Patel A., MacMahon S., Chalmers J., Neal B., Billot L. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572. doi: 10.1056/NEJMoa0802987.

38. Duckworth W., Abraira C., Moritz T. et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139. doi: 10.1056/NEJMoa0808431.

39. Nathan D.M., Buse J.B., Davidson M.B. et al. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabeyes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203. doi: 10.2337/dc06-9912.